Supplemental file 4 Disease free survivals of the entire cohort of patients A 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) Disseminated.

Slides:

Advertisements

Similar presentations

Supplemental file 3 Overall survivals of the entire cohort of patients Overall Survival (months) Cumulative Survival (%)

Advertisements

Overall Survival (months) Cumulative Survival (%) BM negative BM positive P = Supplemental file 5 Overall survivals.

Initial Fixed Costs Response 7,953Name Cost $ 0.10 Resp Rate2.3%Catalogue $ 0.75 List 345,783 $ 0.85CPO $

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Free Phone $25 a month 100 minutes then 35c per min Free Phone $25 a month 100 minutes then 35c per min Free Phone $20 a month 75 minutes then 25c per.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

Su K. Metcalfe, MD, MPH, Michael T

عنوان مقاله: Primary Gastric Lymphoma: Clinicopathologic study of

Lung squamous cell carcinoma

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Intention-to-treat population

Graphing Linear Equations

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

MAP-tau expression in the Yale University Cohort

Graphing / Plotting Points Review

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Survival Outcomes at 3 Years

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Stage Number observed at the start of each stage

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

Leigh Ann White, Joseph Menzin, Jonathan R

II //II // \ Others Q.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential.

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Volume 136, Issue 1, Pages (January 2009)

Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning Yvette L. Kasamon,

Volume 139, Issue 1, Pages e2 (July 2010)

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Solving Equations 3x+7 –7 13 –7 =.

Patients With Celiac Disease and B-Cell Lymphoma Have a Better Prognosis Than Those With T-Cell Lymphoma Thorvardur R. Halfdanarson, Alberto Rubio–Tapia,

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Supplementary Figure 2A

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Primary Cardiac Sarcoma

Issue Highlights Clinical Gastroenterology and Hepatology

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Baseline Characteristics of the Patients – Part I

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

Issue Highlights Clinical Gastroenterology and Hepatology

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Influence of ASGR2 expression on survival.

Demographic Characteristics of Cohort

Presentation transcript:

Supplemental file 4 Disease free survivals of the entire cohort of patients A 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) Disseminated Nasal P = 0.001 Non-nasal B 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) P = 0.033 Stage I Stage II Stage IV

C D 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) Negative EBV DNA SMILE (I) Positive EBV DNA SMILE (I) P = 0.01 D 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) P < 0.001 IPI = 1 IPI = 0 IPI = 2 IPI = 3 IPI = 5

E 20 40 60 80 100 Disease Free Survival (months) Cumulative Survival (%) KIPI = 4 KIPI = 3 KIPI = 2 KIPI = 1 KIPI = 0 P = 0.024